Identification and characterization of M6903, an antagonistic anti-TIM-3 monoclonal antibody
Zhang, Dong, Jiang, Feng, Zaynagetdinov, Rinat, Huang, Hui, Sood, Vanita D., Wang, Hong, Zhao, Xinyan, Jenkins, Molly H., Ji, Qingyong, Wang, Youbin, Nannemann, David P., Musil, Djordje, Wesolowski, John, Paoletti, Andrea, Bartholomew, Tin, Derner, Melissa G., An, Qi, Iffland, Christel, Halle, Joern-Peter
Published in Oncoimmunology (01.01.2020)
Published in Oncoimmunology (01.01.2020)
Get full text
Journal Article
Translational Medicine Guide transforms drug development processes: the recent Merck experience
Dolgos, Hugues, Trusheim, Mark, Gross, Dietmar, Halle, Joern-Peter, Ogden, Janet, Osterwalder, Bruno, Sedman, Ewen, Rossetti, Luciano
Published in Drug discovery today (01.03.2016)
Published in Drug discovery today (01.03.2016)
Get full text
Journal Article
757 M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity
Xu, Chunxiao, Rabinovich, Brain, Deshpande, Amit, Zhou, Xueyuan, Pipp, Frederic Christian, Schweickhardt, Rene, Webb, Lindsay, Yalavarthi, Sireesha, Bourin, Clotilde, Ghatak, Payel, Safi, Barroq, Wollerton, Francisca, Brewis, Neil, Munoz-Olaya, Jose, Belousova, Natalya, Alimzhanov, Marat, Hubensack, Martina, Halle, Joern-Peter, Blaukat, Andree, Moisan, Jacques
Published in Journal for immunotherapy of cancer (01.11.2021)
Published in Journal for immunotherapy of cancer (01.11.2021)
Get full text
Journal Article
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
Berry, Sneha, Giraldo, Nicolas, Nguyen, Peter, Green, Benjamin, Xu, Haiying, Ogurtsova, Aleksandra, Soni, Abha, Succaria, Farah, Wang, Daphne, Roberts, Charles, Stein, Julie, Engle, Elizabeth, Pardoll, Drew, Anders, Robert, Cottrell, Tricia, Taube, Janis M, Tran, Ben, Voskoboynik, Mark, Kuo, James, Bang, Yung-Lue, Chung, Hyun-Cheo, Ahn, Myung-Ju, Kim, Sang-We, Perera, Ayesh, Freeman, Daniel, Achour, Ikbel, Faggioni, Raffaella, Xiao, Feng, Ferte, Charles, Lemech, Charlotte, Meric-Bernstam, Funda, Werner, Theresa, Hodi, Stephen, Messersmith, Wells, Lewis, Nancy, Talluto, Craig, Dostalek, Mirek, Tao, Aiyang, McWhirter, Sarah, Trujillo, Damian, Luke, Jason, Xu, Chunxiao, BoMarelli, Qi, Jin, Qin, Guozhong, Yu, Huakui, Jenkins, Molly, Lo, Kin-Ming, Halle, Joern-Peter, Lan, Yan, Taylor, Matthew, Vogelzang, Nicholas, Cohn, Allen, Stepan, Daniel, Shumaker, Robert, Dutcus, Corina, Guo, Matthew, Schmidt, Emmett, Rasco, Drew, Brose, Marcia, Di Simone, Christopher, Jain, Sharad, Richards, Donald, Encarnacion, Carlos, Taylor, Matthew, Vogelzang, Nicholas, Mier, James, An, Jeongshin, Yang, Yeun-Yeoul, Lee, Won-Hee, Yang, Jinho, Kim, Jong-Kyu, Kim, Hyun Goo, Paek, Se Hyun, Lee, Jun Woo, Woo, Joohyun, Kim, Jong Bin, Kwon, Hyungju, Lim, Woosung, Paik, Nam Sun, Kim, Yoon-Keun, Moon, Byung-In
Published in Journal for immunotherapy of cancer (13.02.2019)
Published in Journal for immunotherapy of cancer (13.02.2019)
Get full text
Journal Article
Abstract 964: Induction of immunogenic cell death and interferon signaling by carboplatin and the ATR inhibitor M6620 may contribute to anti-tumor activity of M6620-carboplatin-avelumab triplet combination in MC38 tumor model
Alimzhanov, Marat, George, Ashwin, Shah, Parantu, Zimmerman, Astrid, Schroeder, Andreas, Falk, Martin, Amendt, Christiane, Halle, Joern-Peter, Blaukat, Andree, Zenke, Frank, Soulard, Patricia
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
Abstract 2269: ATR inhibitor M6620 enhances anti-tumor efficacy of the combination of the anti-PD-L1 antibody avelumab with platinum-based chemotherapy
Alimzhanov, Marat, Soulard, Patricia, Zimmermann, Astrid, Schroeder, Andreas, Mehr, Keyvan Tadjalli, Amendt, Christiane, Sim, Geok Choo, Blaukat, Andree, Halle, Joern-Peter, Zenke, Frank T.
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
Abstract 593: Anti-tumor immunity and efficacy of combination treatment of M6223 and bintrafusp alfa versus the combination of M6223 and anti-PD-L1 in preclinical tumor models
Xu, Chunxiao, Yalavarthi, Sireesha, Bourin, Clotilde, Kelton, Christie, Halle, Joern-Peter, Moisan, Jacques
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article
USE OF ALPHA 1-ANTICHYMOTRYPSIN POLYPEPTIDES OR NUCLEIC ACIDS ENCODING THEM, OR OF A CELL WHICH IS EXPRESSING AN ACT POLYPEPTIDE, OR A NUCLEIC ACID ENCODING IT, FOR TREATMENT AND/OR PREVENTION OF DIABETES-ASSOCIATED AND/OR ARTERIAL POORLY HEALING WOUNDS AND FOR IDENTIFYING PHARMACOLOGICALLY ACTIVE SUBSTANCES
Get full text
Patent
Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, or of a cell which is expressing an ACT polypeptide, or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds and for identifying pharmacologically active substances
Get full text
Patent